News & Views

  • Collaboration to Develop Novel Class of Drug Conjugate
    Dr Amrik Basran, CSO Avacta Group

Collaboration to Develop Novel Class of Drug Conjugate

Aug 01 2018 Read 586 Times

Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston and biotherapeutics and reagents developer Avacta Group, are working together on the development of a new class of Affirmer drug conjugate that selectively releases a potent drug in the tumour microenvironment (TME) without requiring cellular internalisation of the conjugate.

The company and the university have jointly filed for broad patent protection covering Affimers and a wide range of other binders, against oncology, viral and inflammatory targets that are not internalised rapidly enough to be useful in traditional antibody-drug conjugates. It also covers a wide range of drugs to which the binders can be conjugated.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are very excited indeed by this highly novel Affimer drug conjugate concept, the first example of which builds on our own PD-L1 programme and the world-class research of Professor Bachovchin at Tufts University School of Medicine, one of the top US medical schools and research institutes.

“We believe that this new drug conjugate platform is transformational for the business. From our initial discussions with several large pharmaceutical companies, it is clear that there is significant interest and there is certainly the potential for partnering at an early stage once we have the appropriate supporting data from the collaboration with Professor Bachovchin.”

He added that broad patent protection for this dual mode of action therapy would be extremely valuable because it could be applied to a wide range of cancers for which patient response to checkpoint inhibitors alone is not high.

Summarising the role of the new conjugate Dr Amrik Basran, Chief Scientific Officer of Avacta Group, added: “Cancer immunotherapy can be an effective treatment strategy, but pharmaceutical companies’ early enthusiasm has given way to the reality of limited patient responses that the industry is now trying to address. The Affimer-drug conjugate circulates as a single molecule, in which the conjugated drug is inert, until it encounters enzymes selectively expressed in tumours, where the drug is released and through its mechanism of action is designed to turn immunologically “cold” tumours “hot” and receptive to immunotherapy. It is our expectation that this will increase the percentage of responsive patients dramatically and in doing so, it will make a meaningful difference to the lives of a great many cancer patients.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Lab Asia August 2019

August 2019

In this Issue Articles Mass Spectrometry & Spectroscopy 67th ASMS Conference on Mass Spectrometry and Allied Topics Chromatography Using Gas Chromatography for measuring atmo...

View all digital editions

Events

ACS National Meeting & Expo, Fall 2019

Aug 25 2019 San Diego, CA, USA

Microscopy Conference 2019

Sep 01 2019 Berlin, Germany

BMSS Annual Meeting

Sep 03 2019 Manchester, UK

JASIS 2019

Sep 04 2019 Chiba City, Japan

ICMGP 2019

Sep 08 2019 Krakow, Poland

View all events